Gazyva

Gazyva Overdosage

obinutuzumab

Manufacturer:

Roche

Distributor:

DKSH
Full Prescribing Info
Overdosage
No experience with overdosage is available from human clinical trials. In clinical trials with GAZYVA, doses ranging from 50 mg up to and including 2000 mg per infusion have been administered. The incidence and intensity of adverse reactions reported in these studies did not appear to be dose dependent.
Patients who experience overdose should have immediate interruption or reduction of their infusion and should be closely supervised. Consideration should be given to the need for regular monitoring of blood cell count and for increased risk of infections while patients are B cell-depleted.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in